Ajax Therapeutics, Inc. — Form D
Ajax Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2024-05-13. The offering totals $95.0M, of which $95.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-05-13
- Form: D
- Accession: 0001780490-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $95.0M
- Amount sold: $95.0M
- Investors: 21
- Date of first sale: 2024-04-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-513064
Issuer
- Name: Ajax Therapeutics, Inc.
- CIK: 0001780490
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 275 MADISON AVE, 39TH FLOOR, NEW YORK, NY, 10016
- Phone: 917-410-7250
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Ramy Farid | Director | New York, NY |
| Ross Levine | Director | New York, NY |
| Scott Platshon | Director | New York, NY |
| Martin Vogelbaum | Director | New York, NY |
| Martin Vogelbaum | Executive Officer | New York, NY |
| David Schnell | Director | New York, NY |
Other filings by this issuer (2)
More